US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
US6596541B2
(en)
*
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
ES2368733T3
(es)
|
2002-07-18 |
2011-11-21 |
Merus B.V. |
Producción recombinante de mezclas de anticuerpos.
|
EP1639009B1
(en)
|
2003-05-30 |
2013-02-27 |
Merus B.V. |
Fab library for the preparation of a mixture of antibodies
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP1941908B1
(en)
|
2005-10-21 |
2015-08-19 |
Chugai Seiyaku Kabushiki Kaisha |
Therapeutic agent for heart disease
|
ES2568436T3
(es)
|
2006-03-31 |
2016-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Procedimiento para controlar la farmacocinética en sangre de anticuerpos
|
EP2025346B1
(en)
|
2006-04-07 |
2016-08-10 |
Osaka University |
Muscle regeneration promoter
|
US8080248B2
(en)
*
|
2006-06-02 |
2011-12-20 |
Regeneron Pharmaceuticals, Inc. |
Method of treating rheumatoid arthritis with an IL-6R antibody
|
DK2041177T3
(da)
|
2006-06-02 |
2012-02-27 |
Regeneron Pharma |
Højaffinitetsantistoffer mod human IL-6-receptor
|
AU2007285695B2
(en)
|
2006-08-18 |
2012-05-24 |
Ablynx N.V. |
Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
US8153128B2
(en)
*
|
2006-11-30 |
2012-04-10 |
Medimmune Limited |
Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
CN101646459B
(zh)
|
2007-01-23 |
2014-02-12 |
国立大学法人信州大学 |
慢性排斥反应抑制剂
|
NZ601583A
(en)
*
|
2007-05-21 |
2013-08-30 |
Bristol Myers Squibb Co |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
US7906117B2
(en)
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
BRPI0811782A2
(pt)
|
2007-05-21 |
2019-02-26 |
Alder Biopharmaceuticals, Inc. |
anticorpos para il-6 e uso dos mesmos
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
US8062864B2
(en)
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
EP2572729A3
(en)
|
2007-08-10 |
2013-06-05 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human nerve growth factor
|
US20110245473A1
(en)
|
2007-09-26 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-IL-6 Receptor Antibody
|
EP2194066B1
(en)
|
2007-09-26 |
2016-03-09 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
BRPI0817294A2
(pt)
|
2007-09-26 |
2015-03-17 |
Chugai Pharmaceutical Co Ltd |
Método de modificação do ponto isoelétrico de anticorpo via substituição de aminoácido em cdr.
|
MX2010011184A
(es)
*
|
2008-04-11 |
2011-01-20 |
Chugai Pharmaceutical Co Ltd |
Molecula de union de antigeno capaz de unir repetidamente a dos o mas moleculas de antigeno.
|
WO2009140348A2
(en)
|
2008-05-13 |
2009-11-19 |
Novimmune Sa |
Anti-il-6/il-6r antibodies and methods of use thereof
|
NZ589411A
(en)
*
|
2008-05-23 |
2013-01-25 |
Ablexis Llc |
Method of generating single vl domain antibodies in transgenic animals
|
WO2009148148A1
(ja)
|
2008-06-05 |
2009-12-10 |
国立がんセンター総長が代表する日本国 |
神経浸潤抑制剤
|
DK2147594T3
(da)
|
2008-06-27 |
2014-02-10 |
Merus B V |
Antistofproducerende ikke-humane pattedyr
|
AU2012200724B8
(en)
*
|
2008-09-26 |
2014-09-11 |
Chugai Seiyaku Kabushiki Kaisha |
Improved antibody molecules
|
TWI440469B
(zh)
*
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
BRPI0921665A2
(pt)
|
2008-11-13 |
2019-04-16 |
Femta Pharmaceuticals, Inc. |
humanizado anti-il-6 anticorpos
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
US8323649B2
(en)
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
MX2011007049A
(es)
|
2009-02-24 |
2011-08-03 |
Esbatech Alcon Biomed Res Unit |
Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
|
SG10201408247SA
(en)
*
|
2009-02-24 |
2015-02-27 |
Esbatech Alcon Biomed Res Unit |
Methods for identifying immunobinders of cell-surface antigens
|
AR075908A1
(es)
*
|
2009-03-19 |
2011-05-04 |
Chugai Pharmaceutical Co Ltd |
Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo.
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region change body
|
GB0905023D0
(en)
|
2009-03-24 |
2009-05-06 |
Univ Erasmus Medical Ct |
Binding molecules
|
BRPI1013877A2
(pt)
|
2009-04-10 |
2017-08-15 |
Ablynx Nv |
Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r
|
WO2010115995A2
(en)
*
|
2009-04-10 |
2010-10-14 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
DK2798950T4
(da)
|
2009-07-08 |
2023-05-15 |
Kymab Ltd |
Dyremodeller og terapeutiske molekyler
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
BR112012009828B8
(pt)
*
|
2009-10-26 |
2022-10-25 |
Hoffmann La Roche |
Método para a produção de uma imunoglobulina glicosilada e seu uso
|
JP5934652B2
(ja)
|
2009-11-24 |
2016-06-15 |
アルダーバイオ ホールディングス エルエルシー |
Il−6に対する抗体およびその使用
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
MY173363A
(en)
|
2009-12-10 |
2020-01-21 |
Regeneron Pharma |
Mice that make heavy chain antibodies
|
JO3274B1
(ar)
|
2009-12-24 |
2018-09-16 |
Regeneron Pharma |
أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
|
JO3417B1
(ar)
*
|
2010-01-08 |
2019-10-20 |
Regeneron Pharma |
الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
|
TWI609698B
(zh)
|
2010-01-20 |
2018-01-01 |
Chugai Pharmaceutical Co Ltd |
穩定化的含抗體溶液製劑
|
JO3183B1
(ar)
|
2010-01-29 |
2018-03-08 |
Regeneron Pharma |
طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
EP2501817B2
(en)
|
2010-02-08 |
2021-04-21 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
EP3190187A1
(en)
*
|
2010-05-21 |
2017-07-12 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
JP6051049B2
(ja)
|
2010-05-28 |
2016-12-21 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
US9017668B2
(en)
*
|
2010-06-16 |
2015-04-28 |
Trellis Bioscience, Llc |
High affinity human antibodies to human cytomegalovirus (CMV) gB protein
|
AU2011285919C1
(en)
|
2010-08-02 |
2015-09-17 |
Regeneron Pharmaceuticals, Inc. |
Mice that make binding proteins comprising VL domains
|
US9533039B2
(en)
|
2010-09-27 |
2017-01-03 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
|
AR083044A1
(es)
*
|
2010-09-27 |
2013-01-30 |
Regeneron Pharma |
Anticuerpos anti-cd48 y usos de los mismos
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
JO3756B1
(ar)
|
2010-11-23 |
2021-01-31 |
Regeneron Pharma |
اجسام مضادة بشرية لمستقبلات الجلوكاجون
|
ES2847891T3
(es)
|
2010-11-23 |
2021-08-04 |
Vitaeris Inc |
Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
US20120189621A1
(en)
|
2011-01-21 |
2012-07-26 |
Yann Dean |
Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
|
ES2805364T3
(es)
|
2011-02-25 |
2021-02-11 |
Regeneron Pharma |
Ratones ADAM6
|
EP2681243B1
(en)
|
2011-03-03 |
2018-09-05 |
Apexigen, Inc. |
Anti-il-6 receptor antibodies and methods of use
|
CA2830013C
(en)
|
2011-04-01 |
2020-01-07 |
Chugai Seiyaku Kabushiki Kaisha |
Recombinant polypeptide production method
|
EP2579039B1
(en)
|
2011-05-12 |
2017-10-25 |
Regeneron Pharmaceuticals, Inc. |
Neuropeptide release assay for sodium channels
|
JO3412B1
(ar)
|
2011-06-17 |
2019-10-20 |
Regeneron Pharma |
أجسام مضادة ل angptl3 واستخداماتها
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
JP6510234B2
(ja)
|
2011-08-05 |
2019-05-08 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ヒト化ユニバーサル軽鎖マウス
|
JP2014533930A
(ja)
|
2011-09-19 |
2014-12-18 |
カイマブ・リミテッド |
免疫グロブリン遺伝子多様性の操作およびマルチ抗体治療薬
|
EP2747782B1
(en)
|
2011-09-23 |
2018-01-17 |
Ablynx NV |
Prolonged inhibition of interleukin-6 mediated signaling
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
CA2791109C
(en)
|
2011-09-26 |
2021-02-16 |
Merus B.V. |
Generation of binding molecules
|
ES2694153T3
(es)
|
2011-09-30 |
2018-12-18 |
Regeneron Pharmaceuticals, Inc. |
Anticuerpos anti-ErbB3 y usos de los mismos
|
TWI589299B
(zh)
*
|
2011-10-11 |
2017-07-01 |
再生元醫藥公司 |
用於治療類風濕性關節炎之組成物及其使用方法
|
US9943594B2
(en)
|
2011-10-11 |
2018-04-17 |
Sanofi Biotechnology |
Methods for the treatment of rheumatoid arthritis
|
KR20200039028A
(ko)
*
|
2011-10-11 |
2020-04-14 |
사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 |
류마티스 관절염 치료를 위한 조성물 및 이의 이용방법
|
PL3216871T3
(pl)
|
2011-10-17 |
2022-03-21 |
Regeneron Pharmaceuticals, Inc. |
Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy
|
WO2013059548A1
(en)
|
2011-10-19 |
2013-04-25 |
Sanofi |
Compositions and methods for treating cancer using jak2 inhibitor
|
WO2013059426A1
(en)
*
|
2011-10-21 |
2013-04-25 |
The Regents Of The University Of California |
Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof
|
CN103059137A
(zh)
*
|
2011-10-21 |
2013-04-24 |
神州细胞工程有限公司 |
抗hIL6R高亲和力抗体的制备及应用
|
SG10202100485XA
(en)
|
2011-10-28 |
2021-02-25 |
Regeneron Pharma |
Humanized il-6 and il-6 receptor
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
LT2780368T
(lt)
|
2011-11-14 |
2018-03-12 |
Regeneron Pharmaceuticals, Inc. |
Kompozicijos ir būdai raumenų masės padidinimui ir raumenų sustiprinimui, specifiškai antagonizuojant gdf8 ir (arba) aktiviną a
|
KR102024066B1
(ko)
|
2011-11-23 |
2019-09-24 |
비오벤 쓰리 리미티드 |
재조합 단백질 및 그들의 치료적 용도
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
JP6327750B2
(ja)
|
2011-12-20 |
2018-05-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
ヒト化軽鎖マウス
|
US9371383B2
(en)
|
2012-01-31 |
2016-06-21 |
Regeneron Pharmaceuticals, Inc. |
Anti-ASIC1 antibodies and uses thereof
|
MY168748A
(en)
*
|
2012-01-31 |
2018-11-30 |
Regeneron Pharma |
Anti-asic1 antibodies and uses thereof
|
TWI613215B
(zh)
|
2012-02-22 |
2018-02-01 |
再生元醫藥公司 |
抗-大-內皮素-1(big-et-1)抗體及其用途
|
RU2017127772A
(ru)
|
2012-03-02 |
2019-02-04 |
Регенерон Фармасьютикалз, Инк. |
Человеческие антитела к токсинам clostridium difficile
|
WO2013134263A1
(en)
|
2012-03-06 |
2013-09-12 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
DK2825036T3
(en)
|
2012-03-16 |
2018-07-16 |
Regeneron Pharma |
Histidine engineered light chain antibodies and genetically modified rodents to generate them
|
SG11201405164QA
(en)
|
2012-03-16 |
2014-10-30 |
Regeneron Pharma |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
RU2018128915A
(ru)
|
2012-03-16 |
2019-02-18 |
Регенерон Фармасьютикалз, Инк. |
ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К рН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
TWI619729B
(zh)
|
2012-04-02 |
2018-04-01 |
再生元醫藥公司 |
抗-hla-b*27抗體及其用途
|
EA035344B1
(ru)
|
2012-04-20 |
2020-05-29 |
Мерюс Н.В. |
Способ получения двух антител из одной клетки-хозяина
|
JO3820B1
(ar)
|
2012-05-03 |
2021-01-31 |
Regeneron Pharma |
أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
|
EP2858487B1
(en)
|
2012-06-12 |
2019-10-23 |
Regeneron Pharmaceuticals, Inc. |
Humanized non-human animals with restricted immunoglobulin heavy chain loci
|
TW201843172A
(zh)
|
2012-06-25 |
2018-12-16 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
AR092177A1
(es)
|
2012-08-21 |
2015-03-25 |
Sanofi Sa |
Metodos para tratar o prevenir asma administrando un antagonista de il-4r
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
CN118286417A
(zh)
|
2012-09-07 |
2024-07-05 |
瑞泽恩制药公司 |
以il-4r拮抗剂治疗特应性皮炎的方法
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
KR20150084007A
(ko)
|
2012-11-13 |
2015-07-21 |
리제너론 파아마슈티컬스, 인크. |
항-프로키네티신 수용체 (prokr) 항체 및 이의 용도
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
CN109769752A
(zh)
|
2013-02-20 |
2019-05-21 |
瑞泽恩制药公司 |
具有修饰的免疫球蛋白重链序列的非人类动物
|
EP2967013B1
(en)
|
2013-03-13 |
2019-01-16 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
JO3532B1
(ar)
|
2013-03-13 |
2020-07-05 |
Regeneron Pharma |
الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
|
CA2903696A1
(en)
|
2013-03-13 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Common light chain mouse
|
WO2014159595A2
(en)
|
2013-03-14 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to nav1.7
|
CN105189548A
(zh)
|
2013-03-14 |
2015-12-23 |
瑞泽恩制药公司 |
Grem1的人抗体
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
SI3010539T1
(sl)
|
2013-06-21 |
2019-11-29 |
Regeneron Pharma |
Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素a之抗體及其用途
|
EP3564671B1
(en)
|
2013-08-23 |
2021-09-29 |
Regeneron Pharmaceuticals, Inc. |
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
|
LT3046412T
(lt)
|
2013-09-18 |
2019-07-25 |
Regeneron Pharmaceuticals, Inc. |
Histidino pakeitimus lengvoje grandinėje turintys antikūnai ir genetiškai modifikuoti gyvūnai, išskyrus žmogų, išvesti jų gamybai
|
GB201316644D0
(en)
|
2013-09-19 |
2013-11-06 |
Kymab Ltd |
Expression vector production & High-Throughput cell screening
|
CA2925723A1
(en)
|
2013-10-01 |
2015-04-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
EP3063543B1
(en)
|
2013-10-31 |
2020-03-11 |
Regeneron Pharmaceuticals, Inc. |
Competitive ligand binding assay for detecting neutralizing antibodies
|
MX2016006709A
(es)
|
2013-11-20 |
2016-09-08 |
Regeneron Pharma |
Moduladores de aplnr y usos de estos.
|
DE202014010499U1
(de)
|
2013-12-17 |
2015-10-20 |
Kymab Limited |
Targeting von humaner PCSK9 zur Cholesterinbehandlung
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
WO2015095511A2
(en)
*
|
2013-12-20 |
2015-06-25 |
The Scripps Research Institute |
Functional antibodies that modulate cell death and related methods
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
WO2015116852A1
(en)
*
|
2014-01-29 |
2015-08-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating rheumatoid arthritis by administering an il-6r antibody
|
EP3973987B1
(en)
|
2014-02-21 |
2024-01-10 |
Sanofi Biotechnology |
Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma
|
SI3126388T1
(sl)
|
2014-03-11 |
2019-08-30 |
Regeneron Pharmaceuticals, Inc. |
Protitelesa ANTI-EGFRVIII in njihova uporaba
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
BR112016021679A2
(pt)
|
2014-03-21 |
2018-12-04 |
Regeneron Pharmaceuticals, Inc. |
proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
|
AU2015230938C1
(en)
|
2014-03-21 |
2021-10-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
JO3701B1
(ar)
|
2014-05-23 |
2021-01-31 |
Regeneron Pharma |
مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
|
BR112017005110A2
(pt)
|
2014-09-16 |
2018-01-23 |
Regeneron Pharma |
anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
|
SG11201701712WA
(en)
|
2014-09-23 |
2017-04-27 |
Regeneron Pharma |
Anti-il-25 antibodies and uses thereof
|
AU2015334984A1
(en)
|
2014-10-21 |
2017-04-13 |
Ablynx Nv |
Treatment of IL-6R related diseases
|
IL303337A
(en)
|
2014-11-14 |
2023-08-01 |
Regeneron Pharma |
Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist
|
SI3221359T1
(sl)
|
2014-11-17 |
2020-08-31 |
Regeneron Pharmaceuticals, Inc. |
Metode zravljenja tumorja z uporabo bispecifičnega protitelesa CD3XCD20
|
AU2015355150A1
(en)
*
|
2014-12-02 |
2017-06-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating dry eye disease by administering an IL-6R antagonist
|
TWI701258B
(zh)
|
2014-12-19 |
2020-08-11 |
美商再生元醫藥公司 |
流行性感冒病毒血球凝集素之人類抗體
|
TWI710573B
(zh)
|
2015-01-26 |
2020-11-21 |
美商再生元醫藥公司 |
抗伊波拉病毒醣蛋白之人類抗體
|
KR101892883B1
(ko)
|
2015-02-27 |
2018-10-05 |
추가이 세이야쿠 가부시키가이샤 |
Il-6 관련 질환 치료용 조성물
|
WO2016149678A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
CN107771081A
(zh)
|
2015-04-15 |
2018-03-06 |
瑞泽恩制药公司 |
用gdf8抑制剂增加力量和功能的方法
|
JP2016208934A
(ja)
*
|
2015-05-12 |
2016-12-15 |
学校法人日本大学 |
抗イヌインターロイキン−6受容体モノクローナル抗体又は抗体フラグメント及びその利用
|
ES2888801T3
(es)
|
2015-05-19 |
2022-01-07 |
Nat Center Neurology & Psychiatry |
Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM)
|
WO2016195088A1
(ja)
|
2015-06-04 |
2016-12-08 |
国立研究開発法人 国立精神・神経医療研究センター |
Il-6阻害剤を有効成分とする精神疾患治療剤
|
ES2971045T3
(es)
|
2015-07-06 |
2024-06-03 |
Regeneron Pharma |
Moléculas multiespecíficas de unión a antígeno y usos de las mismas
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
CA2995645A1
(en)
|
2015-08-18 |
2017-02-23 |
Regeneron Pharmaceuticals, Inc. |
Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
EP3184547A1
(en)
*
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
MD3394103T2
(ro)
|
2015-12-22 |
2023-11-30 |
Regeneron Pharma |
Combinație de anticorpi anti-PD-1 și anticorpi bispecifici anti-CD20/anti-CD3 pentru tratamentul cancerului
|
AU2016381992B2
(en)
|
2015-12-28 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
EP3402326A1
(en)
|
2016-01-13 |
2018-11-21 |
Regeneron Pharmaceuticals, Inc. |
Rodents having an engineered heavy chain diversity region
|
SG11201806427WA
(en)
|
2016-02-16 |
2018-08-30 |
Regeneron Pharma |
Non-human animals having a mutant kynureninase gene
|
TW202419103A
(zh)
|
2016-03-07 |
2024-05-16 |
法商賽諾菲生物技術公司 |
用於治療類風濕性關節炎之組成物及方法
|
EP3216461A1
(en)
|
2016-03-07 |
2017-09-13 |
Sanofi Biotechnology |
Compositions and methods for treating rheumatoid arthritis
|
RS62769B1
(sr)
|
2016-04-08 |
2022-01-31 |
Regeneron Pharma |
Postupci za lečenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3
|
WO2017184831A1
(en)
*
|
2016-04-20 |
2017-10-26 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for making antibodies based on use of an expression-enhancing locus
|
TW202415767A
(zh)
|
2016-04-20 |
2024-04-16 |
美商再生元醫藥公司 |
基於使用增強表現基因座之製備抗體的組成物及方法
|
US11352446B2
(en)
|
2016-04-28 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
TW202408578A
(zh)
|
2016-05-13 |
2024-03-01 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
RU2021106817A
(ru)
|
2016-05-20 |
2021-04-06 |
Регенерон Фармасьютикалс, Инк. |
Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
|
WO2017201731A1
(en)
|
2016-05-27 |
2017-11-30 |
Beijing Vdjbio Co., Ltd. |
Antibodies, composition and kits comprising same, and methods of use thereof
|
WO2017214089A1
(en)
|
2016-06-06 |
2017-12-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing antibodies with human lambda light chains
|
MY200162A
(en)
|
2016-06-10 |
2023-12-09 |
Regeneron Pharma |
Anti-gitr antibodies and uses thereof
|
JP7102353B2
(ja)
|
2016-06-14 |
2022-07-19 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗c5抗体及びそれらの使用
|
TW201815821A
(zh)
|
2016-07-18 |
2018-05-01 |
美商再生元醫藥公司 |
抗茲卡病毒抗體及使用方法
|
RU2656160C2
(ru)
*
|
2016-08-17 |
2018-05-31 |
Закрытое Акционерное Общество "Биокад" |
Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
KR20240065318A
(ko)
|
2016-09-01 |
2024-05-14 |
리제너론 파아마슈티컬스, 인크. |
Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법
|
CA3037732A1
(en)
|
2016-09-23 |
2018-03-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
|
JP7066691B2
(ja)
|
2016-09-23 |
2022-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性抗muc16-cd3抗体および抗muc16薬物複合体
|
EP3766343B1
(en)
|
2016-11-04 |
2022-05-11 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having an engineered immunoglobulin lambda light chain locus
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
|
KR20190078650A
(ko)
|
2016-11-17 |
2019-07-04 |
리제너론 파아마슈티컬스, 인크. |
항-angptl8 항체를 사용하는 비만의 치료 방법
|
KR20190091290A
(ko)
|
2016-11-29 |
2019-08-05 |
리제너론 파아마슈티컬스, 인크. |
Prlr 양성 유방암 치료 방법
|
US10736961B2
(en)
|
2016-11-29 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
Method of averting opioid addiction
|
BR112019011186A2
(pt)
|
2016-12-01 |
2019-10-08 |
Regeneron Pharma |
conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
|
TW202332696A
(zh)
|
2016-12-01 |
2023-08-16 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
WO2018118713A1
(en)
|
2016-12-22 |
2018-06-28 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
TWI781130B
(zh)
|
2017-01-03 |
2022-10-21 |
美商再生元醫藥公司 |
抗金黃色葡萄球菌溶血素a毒素之人類抗體
|
CN118557758A
(zh)
|
2017-02-10 |
2024-08-30 |
瑞泽恩制药公司 |
用于免疫-pet成像的放射性标记的抗-lag3抗体
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
EP3620531A4
(en)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
|
MX2019014430A
(es)
|
2017-06-01 |
2020-07-14 |
Regeneron Pharma |
Anticuerpos humanos contra bet v 1 y metodos de uso de los mismos.
|
US11208458B2
(en)
|
2017-06-07 |
2021-12-28 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for internalizing enzymes
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
US20190048072A1
(en)
|
2017-06-22 |
2019-02-14 |
Novartis Ag |
USE OF IL-1beta BINDING ANTIBODIES
|
WO2019005897A1
(en)
|
2017-06-28 |
2019-01-03 |
Regeneron Pharmaceuticals, Inc. |
HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
|
KR20210084695A
(ko)
|
2017-07-06 |
2021-07-07 |
리제너론 파마슈티칼스 인코포레이티드 |
당단백질을 만들기 위한 세포 배양 과정
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
TW201915023A
(zh)
|
2017-09-13 |
2019-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
Il-6r抗體、其抗原結合片段及醫藥用途
|
SG11202001160XA
(en)
|
2017-09-29 |
2020-03-30 |
Regeneron Pharma |
Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
|
EP3698808A4
(en)
|
2017-10-20 |
2021-07-14 |
Hyogo College Of Medicine |
MEDICAL COMPOSITION CONTAINING ANTI-IL-6 RECEPTOR ANTIBODIES FOR THE PREVENTION OF POSTOPERATIVE ADHESION
|
MX2020004467A
(es)
|
2017-10-30 |
2020-10-22 |
Sanofi Biotechnology |
Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
|
CA3083452A1
(en)
|
2017-11-30 |
2019-06-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-trkb monoclonal antibodies and methods of use
|
HUE060608T2
(hu)
|
2017-12-05 |
2023-03-28 |
Regeneron Pharma |
Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
|
WO2019118556A1
(en)
|
2017-12-13 |
2019-06-20 |
Regeneron Pharmaceuticals, Inc. |
Anti-c5 antibody combinations and uses thereof
|
JP2021509021A
(ja)
|
2017-12-18 |
2021-03-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
レプチン受容体および/またはgp130に結合する二重特異性抗原結合分子、ならびにその使用方法
|
US11977081B2
(en)
|
2017-12-18 |
2024-05-07 |
Regeneron Pharmaceuticals, Inc. |
ANGPTL8 assay and uses thereof
|
WO2019126123A1
(en)
|
2017-12-22 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
WO2019147867A1
(en)
|
2018-01-26 |
2019-08-01 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to influenza hemagglutinin
|
MX2020008095A
(es)
|
2018-01-31 |
2020-09-24 |
Regeneron Pharma |
Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
JP2021514609A
(ja)
|
2018-02-28 |
2021-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ウイルス混入物質を同定するためのシステムおよび方法
|
JP2021515003A
(ja)
|
2018-03-01 |
2021-06-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
体組成を変更するための方法
|
KR102503356B1
(ko)
|
2018-03-19 |
2023-02-24 |
리제너론 파마슈티칼스 인코포레이티드 |
마이크로칩 모세관 전기영동 분석 및 시약
|
US11667701B2
(en)
|
2018-03-26 |
2023-06-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-PfRH5 antibodies and antigen-binding fragments thereof
|
CN112074538A
(zh)
|
2018-04-30 |
2020-12-11 |
瑞泽恩制药公司 |
结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途
|
SG11202010909RA
(en)
|
2018-05-09 |
2020-12-30 |
Regeneron Pharma |
Anti-msr1 antibodies and methods of use thereof
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
SG11202011232VA
(en)
|
2018-05-17 |
2020-12-30 |
Regeneron Pharma |
Anti-cd63 antibodies, conjugates, and uses thereof
|
EP4023059A1
(en)
|
2018-06-14 |
2022-07-06 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
|
MA52966A
(fr)
|
2018-06-19 |
2021-04-28 |
Regeneron Pharma |
Anticorps anti-facteur xii/xiia et leurs utilisations
|
AU2019290198A1
(en)
|
2018-06-21 |
2021-01-14 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-PSMA x anti-CD28 antibodies and uses thereof
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAx抗-CD3抗體及其用途
|
MD3823665T2
(ro)
|
2018-07-19 |
2024-05-31 |
Regeneron Pharma |
Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
|
MX2021001549A
(es)
|
2018-08-10 |
2021-04-13 |
Regeneron Pharma |
Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera.
|
KR20210049863A
(ko)
|
2018-08-23 |
2021-05-06 |
리제너론 파아마슈티컬스, 인크. |
항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도
|
CA3100035A1
(en)
|
2018-08-27 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Use of raman spectroscopy in downstream purification
|
CA3110891A1
(en)
|
2018-08-29 |
2020-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having rheumatoid arthritis
|
US11754569B2
(en)
|
2018-08-30 |
2023-09-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing protein complexes
|
MX2021004284A
(es)
|
2018-10-23 |
2021-05-31 |
Regeneron Pharma |
Anticuerpos anti-npr1 y usos de los mismos.
|
CA3117945A1
(en)
*
|
2018-11-09 |
2020-05-14 |
University Of Massachusetts |
Anti-cfae antibodies and methods of use
|
EP3883963A1
(en)
|
2018-11-21 |
2021-09-29 |
Regeneron Pharmaceuticals, Inc. |
Anti-staphylococcus antibodies and uses thereof
|
SG11202105948TA
(en)
|
2018-12-19 |
2021-07-29 |
Regeneron Pharma |
Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
|
CA3124168A1
(en)
|
2018-12-19 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
KR20210114927A
(ko)
|
2019-01-16 |
2021-09-24 |
리제너론 파마슈티칼스 인코포레이티드 |
이황화 결합을 특징 짓는 방법
|
BR112021014377A2
(pt)
|
2019-01-31 |
2021-12-28 |
Regeneron Pharma |
Composições e métodos para o tratamento de artrite idiopática juvenil
|
CA3127696A1
(en)
|
2019-02-12 |
2020-08-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for using bispecific antibodies to bind complement and a target antigen
|
CA3128519A1
(en)
|
2019-02-21 |
2020-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
|
WO2020178193A1
(en)
|
2019-03-01 |
2020-09-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method of treatment of sarcoidosis
|
CN113597328A
(zh)
|
2019-03-21 |
2021-11-02 |
瑞泽恩制药公司 |
用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
|
MA55363A
(fr)
|
2019-03-22 |
2022-01-26 |
Regeneron Pharma |
Anticorps multispécifiques egfr x cd28
|
WO2020210551A1
(en)
|
2019-04-10 |
2020-10-15 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies that bind ret and methods of use thereof
|
SG11202111742QA
(en)
|
2019-04-24 |
2021-11-29 |
Sanofi Biotechnology |
Methods of diagnosis and treatment of rheumatoid arthritis
|
CA3138306A1
(en)
|
2019-05-01 |
2020-11-05 |
Sanofi Biotechnology |
Methods for treating or preventing asthma by administering an il-33 antagonist
|
CA3135004A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Improved competitive ligand binding assays
|
WO2020247461A1
(en)
|
2019-06-04 |
2020-12-10 |
Sanofi Biotechnology |
Compositions and methods for treating pain in subj ects with rheumatoid arthritis
|
MA56117A
(fr)
|
2019-06-05 |
2022-04-13 |
Regeneron Pharma |
Animaux non humains ayant un répertoire de chaînes légères lambda limité exprimé à partir du locus kappa et leurs utilisations
|
MX2021015156A
(es)
|
2019-06-11 |
2022-01-18 |
Regeneron Pharma |
Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, y metodos de uso de estos.
|
EP3982997A4
(en)
*
|
2019-06-14 |
2023-09-13 |
Dana-Farber Cancer Institute, Inc. |
ANTIBODIES TO PD-1 AND METHOD OF USE THEREOF
|
AU2020291946A1
(en)
*
|
2019-06-14 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against PD-1 and methods of use thereof
|
WO2020257586A2
(en)
|
2019-06-20 |
2020-12-24 |
Baxalta Incorporated |
Method of treatment with viral-based gene therapy
|
KR20220034878A
(ko)
|
2019-07-16 |
2022-03-18 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
|
BR112022001194A2
(pt)
|
2019-07-24 |
2022-06-07 |
Regeneron Pharma |
Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
|
AU2020349462A1
(en)
|
2019-09-16 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled MET binding proteins for immuno-PET imaging
|
BR112022004885A2
(pt)
|
2019-09-24 |
2022-06-07 |
Regeneron Pharma |
Sistemas e métodos para uso e regeneração de cromatografia
|
US11773156B2
(en)
|
2019-10-28 |
2023-10-03 |
Regeneron Pharmaceuticals, Inc. |
Anti-hemagglutinin antibodies and methods of use thereof
|
CA3158119A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
US11919965B2
(en)
|
2019-12-06 |
2024-03-05 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
|
CA3160521A1
(en)
|
2019-12-06 |
2021-06-10 |
Sanofi Biotechnology |
Methods for treating copd by administering an il-33 antagonist
|
JP2023508360A
(ja)
|
2019-12-23 |
2023-03-02 |
サノフィ・バイオテクノロジー |
Il-33アンタゴニストおよび/またはil-4rアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
|
BR122023021668A2
(pt)
|
2020-01-21 |
2024-01-09 |
Regeneron Pharmaceuticals, Inc. |
Método para determinar a estabilidade de uma proteína de interesse
|
WO2021150970A1
(en)
|
2020-01-22 |
2021-07-29 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor
|
US11999799B2
(en)
|
2020-02-10 |
2024-06-04 |
Regeneron Pharmaceuticals, Inc. |
Anti-TMPRSS2 antibodies and antigen-binding fragments
|
AU2021218675A1
(en)
|
2020-02-11 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Anti-ACVR1 antibodies and uses thereof
|
AU2021228225A1
(en)
|
2020-02-28 |
2022-09-01 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen binding molecules that bind HER2, and methods of use thereof
|
IL296043A
(en)
|
2020-03-06 |
2022-10-01 |
Regeneron Pharma |
Anti-gitro antibodies and their uses
|
KR20210134300A
(ko)
|
2020-04-02 |
2021-11-09 |
리제너론 파아마슈티컬스, 인크. |
항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
|
WO2021226249A1
(en)
*
|
2020-05-06 |
2021-11-11 |
Sorrento Therapeutics, Inc. |
Neutralizing antibodies that bind the sars-cov-2 s protein
|
KR20230009501A
(ko)
|
2020-05-12 |
2023-01-17 |
리제너론 파마슈티칼스 인코포레이티드 |
항-glp1r 길항제 항체 및 이의 이용 방법
|
JP7525762B2
(ja)
*
|
2020-05-18 |
2024-07-31 |
ビオシオン インコーポレイテッド |
Il6rに結合する抗体及びその使用
|
CA3179819A1
(en)
|
2020-05-26 |
2021-12-02 |
Alina Baum |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
BR112022024020A2
(pt)
|
2020-05-26 |
2023-04-04 |
Feist Eugen |
Composições compreendendo um anticorpo contra receptor de interleucina-6 para tratamento de artrite reumatoide e métodos de uso das mesmas
|
JP2023527200A
(ja)
|
2020-05-29 |
2023-06-27 |
サノフィ・バイオテクノロジー |
関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法
|
US20230227539A1
(en)
*
|
2020-06-16 |
2023-07-20 |
Hifibio (Hk) Limited |
Methods and compositions related to neutralizing antibodies against human coronavirus
|
TW202221024A
(zh)
*
|
2020-08-07 |
2022-06-01 |
美商索倫多醫療公司 |
結合sars-cov-2 s蛋白之中和抗體
|
AU2021327238A1
(en)
|
2020-08-20 |
2023-04-27 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists
|
EP4204449A1
(en)
|
2020-08-26 |
2023-07-05 |
Regeneron Pharmaceuticals, Inc. |
Method of treating an allergy with allergen-specific monoclonal antibodies
|
WO2022047108A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
KR20230066386A
(ko)
|
2020-09-11 |
2023-05-15 |
리제너론 파마슈티칼스 인코포레이티드 |
항원 특이적 항체의 확인 및 제조
|
EP4214234A1
(en)
|
2020-09-18 |
2023-07-26 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof
|
CA3194111A1
(en)
|
2020-10-05 |
2022-04-14 |
Christine XU |
Methods for treating asthma in pediatric subjects by administering an il-4r antagonist
|
AU2021366691B2
(en)
|
2020-10-22 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Anti-FGFR2 antibodies and methods of use thereof
|
CN116940347A
(zh)
|
2020-11-25 |
2023-10-24 |
里珍纳龙药品有限公司 |
使用非水性膜乳化的持续释放调配物
|
JP2024500409A
(ja)
|
2020-12-17 |
2024-01-09 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タンパク質封入マイクロゲルの作製
|
IL303542A
(en)
|
2020-12-18 |
2023-08-01 |
Regeneron Pharma |
Immunoglobulin proteins that bind to NPR1 agonists
|
IL303868A
(en)
|
2020-12-23 |
2023-08-01 |
Regeneron Pharma |
Nucleic acids encoding anchor-modified antibodies and uses thereof
|
MX2023008527A
(es)
|
2021-01-20 |
2023-07-28 |
Regeneron Pharma |
Metodos para mejorar el valor proteico en cultivo celular.
|
US20220404369A1
(en)
|
2021-03-03 |
2022-12-22 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
WO2022187626A1
(en)
|
2021-03-05 |
2022-09-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments
|
AU2022243005A1
(en)
|
2021-03-26 |
2023-10-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
BR112023021256A2
(pt)
|
2021-04-20 |
2023-12-12 |
Regeneron Pharma |
Anticorpos humanos para artemina e métodos de uso dos mesmos
|
BR112023023067A2
(pt)
|
2021-05-04 |
2024-01-30 |
Regeneron Pharma |
Receptores de antigénios quiméricos com especificidade mage-a4 e usos dos mesmos
|
JP2024517844A
(ja)
|
2021-05-04 |
2024-04-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
多重特異性fgf21受容体アゴニスト及びそれらの使用
|
CN117730099A
(zh)
|
2021-05-11 |
2024-03-19 |
瑞泽恩制药公司 |
抗tmprss6抗体及其用途
|
EP4348234A1
(en)
|
2021-06-01 |
2024-04-10 |
Regeneron Pharmaceuticals, Inc. |
Micropchip capillary electrophoresis assays and reagents
|
AR126001A1
(es)
|
2021-06-01 |
2023-08-30 |
Symphogen As |
Anticuerpos y composiciones anti-nkg2a
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
CA3226042A1
(en)
|
2021-07-05 |
2023-01-12 |
Regeneron Pharmaceuticals, Inc. |
Utilization of antibodies to shape antibody responses to an antigen
|
AU2022311906A1
(en)
|
2021-07-14 |
2024-01-25 |
Regeneron Pharmaceuticals, Inc. |
Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
|
MX2024001189A
(es)
|
2021-07-26 |
2024-02-27 |
Sanofi Biotechnology |
Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r.
|
TW202326138A
(zh)
|
2021-09-08 |
2023-07-01 |
美商再生元醫藥公司 |
用於定量抗體及其他含Fc蛋白之高通量及基於質譜之方法
|
CN118139881A
(zh)
|
2021-09-20 |
2024-06-04 |
瑞泽恩制药公司 |
控制抗体异质性的方法
|
IL311245A
(en)
|
2021-10-07 |
2024-05-01 |
Regeneron Pharma |
Systems and methods for pH modeling and control
|
EP4413359A1
(en)
|
2021-10-07 |
2024-08-14 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
US20230183362A1
(en)
|
2021-10-20 |
2023-06-15 |
Sanofi Biotechnology |
Methods for treating prurigo nodularis by administering an il-4r antagonist
|
EP4419142A2
(en)
|
2021-10-22 |
2024-08-28 |
Regeneron Pharmaceuticals, Inc. |
Factor xi a2 domain-binding antibodies and methods of use thereof
|
AU2022376179A1
(en)
|
2021-10-26 |
2024-05-16 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
WO2023092052A1
(en)
|
2021-11-19 |
2023-05-25 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for reducing centralized pain
|
AU2022408149A1
(en)
|
2021-12-06 |
2024-05-23 |
Regeneron Pharmaceuticals, Inc. |
Antagonist anti-npr1 antibodies and methods of use thereof
|
US20230296559A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
WO2023212586A1
(en)
|
2022-04-27 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Methods for selecting patients for treatment with an ngf antagonist
|
WO2023225098A1
(en)
|
2022-05-18 |
2023-11-23 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
|
WO2024015816A1
(en)
|
2022-07-12 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
|
WO2024047021A1
(en)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
|
WO2024102369A1
(en)
|
2022-11-07 |
2024-05-16 |
Regeneron Pharmaceuticals, Inc. |
Factor xi catalytic domain-binding antibodies and methods of use thereof
|
WO2024107752A2
(en)
|
2022-11-15 |
2024-05-23 |
Onestone Therapeutics Llc |
Compositions and methods for immunomodulatory bifunctional fusion molecules
|
WO2024130048A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
WO2024130165A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
|
WO2024152014A1
(en)
|
2023-01-13 |
2024-07-18 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
WO2024158961A1
(en)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based characterization of antibodies co-expressed in vivo
|
US20240245779A1
(en)
|
2023-01-25 |
2024-07-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of modeling liquid protein composition stability
|
WO2024163708A1
(en)
|
2023-02-01 |
2024-08-08 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
WO2024173248A1
(en)
|
2023-02-13 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Treatment of muscle related disorders with anti-human cacng1 antibodies
|
WO2024173876A1
(en)
|
2023-02-17 |
2024-08-22 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|